(NASDAQ:AVGR) shares saw heavy trading volume with 2,241K shares changing hands by the end of trading on Wednesday. Overall, volume was up 82.48% over the stocks normal daily volume.
Short traders are more bullish on shares of the company of late if you look at the motion in short interest. The firm recorded a fall in short interest from September 29, 2017 to October 13, 2017 of -44.15%. Short shares fell from 2,641,164 to 1,475,190 over that timeframe. The short-interest ratio decreased to 1.0 and the short interest percentage is 0.05% as of October 13.
A few notable investment firms have updated their holdings. As of the end of the quarter Blackrock Inc. had acquired a total of 399 shares growing its position 15.0%. The value of the company’s investment in Avinger Inc. Cmn went from $1,000 to $1,000 decreasing 0.0% for the reporting period. As of quarter end Morgan Stanley had bought 3,037 shares growing its holdings by 270.4%. The value of the investment in (AVGR) increased from $1,000 to $2,000 a change of 100.0% quarter over quarter.
As of the end of the quarter Goldman Sachs Group Inc had sold 118,561 shares trimming its stake by 92.2%. The value of the total investment in Avinger Inc. Cmn went from $58,000 to $4,000 a change of $54,000 quarter to quarter. As of the end of the quarter Millennium Management LLC had sold a total of 25,004 shares trimming its position 9.2%. The value of the investment in Avinger Inc. Cmn decreased from $121,000 to $93,000 decreasing 23.1% since the last quarter.
In the market the company is trading up by 9.85% since yesterday’s close of 0.228. The company currently has a P/E ratio of N/A and the market cap of the company is 7.88M. In the last earnings report the EPS was $-2.19 with 31.54M shares currently outstanding.
Avinger, Inc., launched on March 8, 2007, is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and select European markets. The Business’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris..